Cyrille Tupin, Chief executive officer of Abionyx Pharma, a new generation biotechnology company, spoke at the press conference to present the results of the Racers clinical study, which evaluates the efficacy of the new drug Cer-001 in the treatment of septic patients with high risk of developing acute kidney injury (Aki).
#Cyrille #Tupin #Encouraging #results #Cer001 #studio #Racers
"It is a fact that in Italy there are millions of smokers who are unwilling or unable to quit smoking....
How important is the quality of the air we breathe, the quality of our sleep and the spaces we inhabit...
An investment of 170 million euros, between research funding and scientific dissemination projects, and almost 2,200 researchers supported in 176...
"MSD's investment is a sign of how important research is and how strong our companies are. We have a treasure...
"The European Community, on the basis of a precautionary principle for air quality, has set parameters that will be further...
Thus the president and CEO of Bsp Pharmaceuticals Spa, today in Rome at the presentation of the ten-year investment of...
